glp-1 news today 2025 november 5 Eli Lilly to seek approval of new weight-loss drug this year In U.S., GLP-1 Usage Reaches

GLP-1 receptor agonists appear to have direct effects on mental health and behavior that go beyond what youd expect from weight loss alone

The first-time AOM semaglutide prescribing rate was 0.1% in January 2024 and reached 0.2% by July 2024

2.8 Immunohistochemistry assay Paraffin-embedded transplanted kidney tissues were sectioned at 5 m thickness

These agents include: Tirzepatide (Mounjaro, Zepbound though technically a dual GIP/GLP-1 receptor agonist) Semaglutide (Ozempic, Wegovy, Rybelsus) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Exenatide (Byetta, Bydureon) They are widely used in both endocrinology and obesity medicine for managing diabetes, weight, and cardiovascular risk